Rocket Fuel


    

Print    Email
Decrease (-) Restore Default Increase (+)


Breast Cancer Clinical Trials

 Please check with your doctor or call 1-855-HCH-HOPE (424-4673) to find out if you qualify for any of these studies. 

Trial  #

Trial Sub- type 

Title

RTOG 1005
NCI

 New.jpg

 

  • pStage I, II breast cancer
  • pStage 0 breast cancer with nuclear grade 3 DCIS and patient age < 50 years
  • ypStage 0, I, II breast cancer resected by lumpectomy after neoadjuvant systemic therapy

A Phase III trial of accelerated whole breast irradiation with hypofractionation plus concurrent boost versus standard whole breast irradiation plus sequential boost for early-stage breast cancer. Learn more.

CDX011-04
Sponsor:
Celldex Therapeutics
New.jpg

Metastatic Triple-Negative Breast Cancer

A Randomized Multicenter Pivotal Study of  CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

ECOG E1Z11
NCI

 

  • Estrogen and/or progesterone • receptor positive, histologically confirmed stage I-III breast adenocarcinoma
  • Completed recommended local and adjuvant therapy for breast cancer
  • Plan to treat with anastrozole for at least 12 months

A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)

NSABP-B-43
NCI

 

DCIS
HER2 -positive

A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma in Situ Resected by Lumpectomy. Learn more.

NSABP –B –47
NCI

 

HER2-Low ( 2+)

A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer. Learn more.

ML28257
Sponsor
Genentech

Metastatic
HER2-positive

An Observational Cohort Study Of Treatment Patterns And Outcomes In Patients With HER2 Positive (HER2+) Metastatic Breast Cancer

CBKM120F2303
Sponsor
Novartis Pharmaceuticals

Metastatic
HER2-negative
HR - positive

A phase III randomized, double blind, placebo controlled study of BKM120 with fulvestrant, in postmenopausal women with hormone receptor-positive HER2-negative AI treated, locally advanced or metastatic breast cancer who progressed on or after mTOR inhibitor based treatment

CRAD001Y2413
Sponsor
Novartis Pharmaceuticals Corp.

Metastatic
HER2- negative
HR – positive
Front - line

An open-label, phase II, single-arm study of everolimus in combination with letrozole in the treatment of postmenopausal women with estrogen receptor positive metastatic breast cancer

S1207
Lead Group:
SWOG

Metastatic
HER2- negative
ER or PR– positive
Adjuvant Therapy

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. Learn more.

?
?
©  2014 

Holy Cross Hospital | 1500 Forest Glen Road, Silver Spring, MD 20910 | 301-754-7000